Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit.
Advanced breast cancer
absolute lymphocyte count
dynamic changes
eribulin
overall survival
post-progression survival
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
14
04
2021
revised:
24
04
2021
accepted:
26
04
2021
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
We investigated the usefulness of dynamic changes in absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive markers for survival benefit including post-progression survival (PPS). We retrospectively investigated 94 advanced breast cancer (ABC) patients who underwent eribulin therapy between July 2011 and June 2020. The multivariate analysis showed that high baseline ALC and low NLR were independent predictive markers for overall survival (OS) (p=0.007 and p=0.011, respectively) and PPS (p=0.005 and p=0.007, respectively). Dynamic changes in ALC were also associated with OS and PPS (p=0.015, and p=0.026, respectively) and were an independent predictive marker for PPS (p=0.021). Baseline ALC and NLR and dynamic changes in ALC during eribulin therapy were significantly associated with survival benefit including PPS for patients with ABC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
We investigated the usefulness of dynamic changes in absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive markers for survival benefit including post-progression survival (PPS).
PATIENTS AND METHODS
METHODS
We retrospectively investigated 94 advanced breast cancer (ABC) patients who underwent eribulin therapy between July 2011 and June 2020.
RESULTS
RESULTS
The multivariate analysis showed that high baseline ALC and low NLR were independent predictive markers for overall survival (OS) (p=0.007 and p=0.011, respectively) and PPS (p=0.005 and p=0.007, respectively). Dynamic changes in ALC were also associated with OS and PPS (p=0.015, and p=0.026, respectively) and were an independent predictive marker for PPS (p=0.021).
CONCLUSION
CONCLUSIONS
Baseline ALC and NLR and dynamic changes in ALC during eribulin therapy were significantly associated with survival benefit including PPS for patients with ABC.
Identifiants
pubmed: 34083304
pii: 41/6/3109
doi: 10.21873/anticanres.15095
doi:
Substances chimiques
Biomarkers
0
Furans
0
Ketones
0
eribulin
LR24G6354G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3109-3119Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.